Reimbursement Review Reports


( Last Updated : August 1, 2021)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

 

Brand Name Sort descending Generic name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete Oct 27, 2015 May 19, 2016
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Do not reimburse Active Aug 25, 2020 Jun 23, 2021
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete Dec 20, 2016 Jun 20, 2017
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Reimburse with clinical criteria and/or conditions Active Jun 25, 2020 Mar 24, 2021
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete Mar 15, 2007 Sep 26, 2007
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn Nov 3, 2006